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Abstract
K-ras is essential for embryogenesis and its mutations are involved in human developmental syndromes and cancer. To
determine the consequences of K-ras activation in urothelium, we used uroplakin-II (UPK II) promoter driven Cre
recombinase mice and generated mice with mutated KrasG12D allele in the urothelium (UPK II-Cre;LSL-K-rasG12D). The UPK II-
Cre;LSL-K-rasG12D mice died neonatally due to lung morphogenesis defects consisting of simplification with enlargement of
terminal air spaces and dysmorphic pulmonary vasculature. A significant alteration in epithelial and vascular basement
membranes, together with fragmentation of laminin, points to extracellular matrix degradation as the causative mechanism
of alveolar and vascular defects. Our data also suggest that altered protease activity in amniotic fluid might be associated
with matrix defects in lung of UPK II-Cre;LSL-K-rasG12. These defects resemble those observed in early stage human neonatal
bronchopulmonary dysplasia (BPD), although the relevance of this new mouse model for BPD study needs further
investigation.
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Introduction
Ras proteins, a super-family of cell membrane GTPases, are key
regulators of pathways involved in cell survival, proliferation and
differentiation [1]. Activating somatic point mutations of Ras are
very frequent in cancer [2]. Some recent studies have demon-
strated that germline Ras mutations play a role in a sub-group of
developmental disorders collectively known as neuro-facial-cardio-
cutaneous syndromes [3]. Additionally, mouse models have shown
an essential role for K-ras in embryogenesis [4,5]. Oncogenic Ras
somatic mutations stabilize the GTP-bound conformation of the
protein, constitutively activating their effector pathways and their
biological effects being dependent upon the type of mutation and
the cellular context [6]. Mutations found in developmental
disorders [7] are also activating mutations, and in fact the
widespread expression of mutated K-rasG12D allele in the embryos
is lethal due to impaired placental function [8] including heart and
brain development defects [9]. However, its conditional expression
in epithelia causes hyperplasia and dysplasia, sometimes leading to
carcinomas [9].
Urothelial expression of H-ras results in superficial papillary
bladder neoplasms in the adult mice [10,11]. The role of K-ras in
the urothelial cells is less well understood [12], although some
recent works have shown its participation in bladder hyperplasia
[13] and the implication of RAS/MAPK signaling in urothelial
carcinoma in situ [14]. We here describe a mouse with conditional
activation of K-rasG12D in urothelium (uroplakin(UPK)II-Cre;LSL-K-
rasG12D). These mice die at neonatal stage due to lung develop-
mental defects resembling human neonatal bronchopulmonary
dysplasia (BPD), a chronic neonatal lung disease associated with
premature birth and currently considered more of a developmen-
tal disorder with impairment of lung alveolarization [15,16].
Materials and Methods
Ethics Statement
The animal experiments were conducted in accordance with the
recommendations in the Guide for the Care an Use of Laboratory
Animals of the National Research Council. The protocol was
approved by the Institutional Animal Care and Use Committee of
the Beth Israel Deaconess Medical Center (Protocol number: 120–
2008). Pregnant mice were euthanized by cervical dislocation.
Fetuses extracted from the uterus and neonate mice were
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euthanized by decapitation. All efforts were made to minimize
suffering.
Gene constructs and generation of transgenic mice
We generated a transgenic mouse that expresses the Cre
recombinase enzyme in bladder epithelium by utilizing the
urothelium-specific promoter uroplakin (UPK)-2 (3.6 Kb), as
previously reported [17]. With a PCR-based approach we cloned
mouse UPK II promoter (Accession number: EF467361) from
BAC (bacterial artificial chromosome) clone RP24-308H8. During
the cloning process we noticed that a portion of the reported
sequence of UPK II promoter region (Accession number: U14421)
was miscloned because of opposite insertion of two SacI restriction
enzyme sites (from 21262 to 22805 from Exon1) in UPK II
promoter. Microinjection of the purified constructs in the
pronuclei of fertilized eggs from C57/BL mice was performed
for generation of transgenic mice UPK II-Cre at Beth Israel
Deaconess Medical Center transgenic facility.
Mouse strains and experiments with mice
For confirmation of urothelium-restricted expression of UPK II,
a reporter strain was generated by interbreeding the UPK II-Cre
strain to ROSA-Stop -Lox-YFPmice. Post-natal day 1 (P1) mice were
sacrificed by decapitation and tissues were fixed in 4% PFA
overnight, then in 20% sucrose and finally included in OCT and
snap frozen. The whole lung, ureter and bladder and represen-
tative samples from placenta and yolk sac were evaluated for YFP
expression. A Lox-Stop-Lox (LSL)-K-rasG12D mouse strain (Balb-C
background), obtained from Jackson Laboratories, was bred to
UPK II-Cre mice (C57BL background). The finding of a vaginal
plug was considered as day 0.5 of pregnancy. Early lethality (day
P1) appeared in the first litter of UPK II-Cre;LSL-K-rasG12D mice.
Observational studies were then performed in two additional
litters, with observation of pregnant mother each two hours and
hourly litter observation of breathing and activity from birth,
thereby ensuring prompt retrieval of non-surviving neonates and
adequate tissue processing of tissues. After whole lethality was
confirmed, all newborn (P1) mice of each litter were sacrificed by
decapitation in the first 2-6 hours of life, before spontaneous death
of any of the pups. Embryos (E14.5, E17.5 and E19.5) were
collected with the amniotic sac intact and AF volume was
determined. Lungs and the rest of organs were snap-frozen or
fixed in 4% paraformaldehyde. The term ‘controls’ refers to
littermates Cre recombinase (-) mice. Mice were maintained at the
Beth Israel Deaconess Medical Center animal facility under
standard conditions.
Histological techniques
Paraformaldehyde-fixed, paraffin-embedded 5 mm sections
were treated with 10 mM citrate buffer for antigen retrieval
and standard immunohistochemical techniques. Primary anti-
bodies: anti-pan-laminin (1:250; Sigma-Aldrich, St. Louis,
MO) and anti-CD34 (1:50; Abcam, Cambridge, MA). Bioti-
nylated secondary antibodies (1:200) and Vectastain ABC kit
were used according to manufacturer’s instructions (Vector
Laboratories, Burlingame, CA). 59-Bromo-29-doxyuridine (Sig-
ma-Aldrich, St. Louis, MO) was injected intraperitoneally
(10 mg/gr. body weight) 2 hours before sacrifice and tissues
were labeled using the BrdU Labeling and detection Kit III
(Roche, Indianapolis, IN). For BrdU quantification, we
analyzed digital images by counting the number of BrdU
labeled nuclei in each 200 mm segment of urothelium. For
immunofluorescence, 5 mm frozen sections were fixed in
acetone at 220uC. Primary antibodies: anti-CD31 (1:50; BD
Biosciences Pharmingen, Sparks, MD), anti-CD34 (1:50;
Abcam, Cambridge, MA), anti-laminin (1:100, Sigma-Aldrich,
St. Louis, MO), anti-laminin b1 (1:50; Santa Cruz Biotech-
nology, Santa Cruz, CA), anti-collagen IV a-1 (1:100; Abcam,
Cambridge, MA), anti-nidogen/entactin (1:200; Millipore,
Billerica, MA), anti-E-cadherin (1:100; Santa Cruz Biotech-
nology, Santa Cruz, CA), anti-VEGF (10 mg/ml; Thermo
Fisher Sci, Rockford, IL), anti-MMP-1 (1:100; EMD Biosci-
ences, Gibbstown, NJ), anti-MMP-3 (1:100; EMD Biosciences,
Gibbstown, NJ), and anti-MMP-13 (1:100; EMD Biosciences,
Gibbstown, NJ). Sections were subsequently labeled with
fluorescein- or rhodamine-conjugated secondary antibodies
(Jackson Immunoresearch, West Grove, PA) and nuclei
counterstained with DAPI. Quantification of lung terminal
air-space area was performed, after exclusion of large vessels or
bronchi, with the Image J software (NIH, Bethesda, MD); both
total and mean air space were normalized to lung surface and
expressed as a ratio to control lung.
Genotyping
Genotype of transgenic mice was determined by PCR in
genomic DNA isolated from mice tails. To exclude Cre-mediated
excision of the Stop-cassette in lung, we performed specific PCR of
DNA isolated from lung, placenta and bladder using the Qiagen
DNAeasy Blood&tissue kit (Qiagen, Valencia, CA). Sex was
genotyped as reported [18].
Amniotic fluid determinations
Lactate in AF samples was measured with the Lactate Assay Kit
(Eton Bioscience Inc, Cambridge, MA) according to manufactur-
er’s instructions. VEGF and sFLT1 were measured in AF samples
with VEGF ELISA kit mouse (EMD Biosciences, Gibbstown, NJ)
and Quantikine Mouse sVEGF R1 kit (R&D Systems, Minneap-
olis, MN).
SDS-PAGE, Western Blot (WB) and zymography
Samples (1 ml of amniotic fluid samples or purified protein
from lung or bladder) were denatured with SDS sample buffer.
Samples for E-cadherin WB were prepared with NP-40 Lysis
Buffer (Boston Bioproducts, Boston, MA). Primary antibodies:
anti-laminin b1 (1:500; Millipore, Billerica, MA), anti-E-
cadherin (1:1000; BD Biosciences Pharmingen, Sparks, MD),
anti-MMP-1 (1:1000; EMD Biosciences, Gibbstown, NJ), anti-
MMP-2 (1:250; Santa Cruz Biotechnology, Santa Cruz, CA),
anti-MMP-3 (1:500; Sigma-Aldrich, St. Louis, MO), anti-
MT1-MMP (1:500; EMD Biosciences, Gibbstown, NJ) and
anti-actin (1:1000; Sigma-Aldrich, St. Louis, MO). After
incubation with HRP-conjugated secondary antibodies (Sig-
ma-Aldrich, St. Louis, MO), an enhanced chemiluminescence
detection system (Pierce Biotechnology, Rockford, IL) was
used for development. For zymography, 10% SDS-PAGE
gels were copolymerized with gelatin (0.1 mg/L) or casein
(1 mg/L) (Sigma-Aldrich, St. Louis, MO). Between 1 and 5 ml
of amniotic fluid were used for zymography, which was
performed as previously described [19].
Statistical analysis
Data are expressed as mean 6 SE. Statistical analysis was
performed using SPSS version 15.0 (SPSS Inc.). Tests used were
non-parametric Mann-Whitney (unpaired, two-tailed), and, when
appropriate, Student’s T-test. Statistical significance was estab-
lished as P#0.05.
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Results
UPK II-Cre expression is restricted to urothelium
A transgenic mouse that expressed the Cre recombinase enzyme
in bladder epithelium was generated by utilizing the urothelium
specific promoter uroplakin II (UPK II). To confirm urothelium-
restricted expression of the UPK II-Cre mice, a reporter strain was
obtained by breeding the UPK II-Cre with Rosa-R26R-YFP floxed
mice. When compared to control mice, YFP expression at both
day P1 and E17.5 was only detected in the urothelial cells of
bladder (Figure 1A–B) and the ureter (Figure 1C–D) of UPK II-
Cre;Rosa-Stop-YFP+/+, but not in lung (Figure 1E–F). YFP
expression was not detected in the placenta or the yolk sac
(Figure 1G–J) at E17.5 and E19.5. YFP expression was not only
confined to the umbrella cell layer, but also detected in the basal
and suprabasal layers of the urothelium [20]. Absence of Cre-
mediated excision of the Stop cassette in lung was further
confirmed by PCR for the recombined YFP gene, when compared
to the bladder DNA from UPK II-Cre;Rosa-Stop-YFP mice at E19.5
(Figure 1K) and P1.
Early lethality in UPK II-Cre;K-rasG12D mice
Heterozygous mating of UPK II-Cre and K-rasG12D mice
(Figure 2A) generated an average of 9.75 (range: 7–12) mice/
litter. Sex ratio was well balanced (59.45% females, 40.55% males;
x2 test, P=0.32). The 8 litters evaluated included 33 mice with the
genotype UPK II-Cre+/K-rasG12D (UPK II-Cre;LSL-K-rasG12D),
confining to the expected Mendelian ratio. After observation of
three double positive litters confirmed a complete lethality in the
first 12 hours after birth (18/18 vs. 0/15; x2 test, P,0.001), the
rest of litters were sacrificed within 6 hours after birth and further
evaluated. Mice with the UPK II-Cre;LSL-K-rasG12D genotype
exhibited significantly lower weight (UPK II-Cre;LSL-K-rasG12D vs.
control: 1.31260.208 gr. vs. 1.41960.096 gr.; P=0.04) and had
minimal mobility and activity.
Urothelial expression of K-rasG12D is associated with
bladder epithelial hyperplasia
K-rasG12D expression induces proliferation and hyperplasia in
epithelial cells [9]. When compared to the control mice,
urothelium from UPK II-Cre;LSL-K-rasG12D mice showed a
significant absolute increase in cell number, consistent with
hyperplasia, both at E17.5 (Figure 2B–C) and P1 (Figure 2D–F).
BrdU staining at E17.5 revealed increased urothelial proliferation
in UPK II-Cre;LSL-K-rasG12D mice when compared to control mice
(6+2 positive nuclei/200 mm vs. 1.33+0.81; P=0.01) (Figure 2G–
H). No dysplasia or tumors were detected in any of the bladders.
Impaired lung morphogenesis in the UPK II-Cre;LSL-K-
rasG12D lungs
Macroscopically, lungs from UPK II-Cre;LSL-K-rasG12D mice
exhibited patchy hemorrhagic areas on the lung surface, with
normal pleura and lobar septation. Lungs from the UPK II-
Cre;LSL-K-rasG12D mice and the control mice had similar lung
weights at E17.5 (UPK II;LSL-K-rasG12D vs. control: 31.864.32 vs
32.3563.07 mg; P=0.78), E19.5 (30.7164.47 vs 33.8964.54 mg;
P=0.10) and P1 (31.462.36 vs 33.0161.26 mg; P=0.52).
Digestive tract, trachea and heart did not show any abnormality.
Neither dilatation nor obstruction or gross abnormalities were
observed in upper and lower urinary tract. Microscopically, there
were no differences between UPK II-Cre;LSL-K-rasG12D and
controls with regard to the pseudo-glandular phase of lung
development (E14.5) (Figure 3A–B). Differences in lung morphol-
ogy were not evident until E17.5, corresponding to the transition
between canalicular and saccular stages or to the early saccular
phase of lung morphogenesis [21]. Creation of terminal air spaces
from distal airways was considerably altered in UPK II-Cre;LSL-K-
rasG12D mice starting E17.5 (Figure 3C–D), and at E19.5
(Figure 3E–F). At P1, the striking impairment of septation in
UPK II-Cre;LSL-K-rasG12D resulted in significantly fewer but larger
terminal air spaces (sacculi) [22], which showed a simplified
morphology (Figure 3G–H). Morphometry demonstrated a
Figure 1. Characterization of the UPK II-Cre;Rosa-Stop-YFP reporter mice. A–J: UPK II-Cre;Rosa-Stop-YFP+/+ reporter mice reveal fluorescence
only in the bladder urothelium (x200) (A,B) and ureter urothelium (x200) (day 1, P1) (white arrow) (C,D), but not in lung (x200) (P1) (E,F), placenta
(x200) (E19.5) (G,H) or yolk sac (x200) (E19.5) (I,J) among other negative tissues. K: PCR for recombinant UPK II-YFP was only positive in UPK II-
Cre;Rosa-Stop-YFP+/+ bladder (E19.5).
doi:10.1371/journal.pone.0095888.g001
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remarkable decrease in both total airspace and mean area of
airspaces at E17.5, which indicated a possible impaired septation
leading to a lower number of terminal air spaces (Figure 3I–J). A
similar result was observed at E19.5 (data not shown). On day P1,
increased total airspace was observed and especially in mean
airspace area upon first lung insufflations (Fig. 3I–J). No
inflammatory infiltrates or fibrosis were observed in P1 lung when
evaluated by the Masson’s tri-chrome staining (Figure 3K–L).
Thus, the observed morphologic pattern suggested a normal
branching of lungs with only late impairment in the process of
septation. K-rasG12D-Lox1A sequence was not found in lungs of UPK
II-Cre;LSL-K-rasG12D mice (Figure 3M). The lung defects in the
UPK II-Cre;LSL-K-rasG12D resembled the early phase of human
neonatal bronchopulmonary dysplasia, a condition in which
alveolar enlargement and simplification are the key features in
neonatal lungs (Figure S1, A). We did not observe fibrosis in the
UPK II-Cre;LSL-K-rasG12D mice at P1, while interstitial fibrosis is
noticed in human BPD only after post-natal prolonged oxygen
supplementation and mechanical ventilation (Figure S1, B) [15].
Extracellular matrix and vascular defects in the lungs
from UPK II-Cre;LSL-K-rasG12D mice
Because interactions between extracellular matrix (ECM) and
epithelial/endothelial cells are critical for lung development, we
examined ECM distribution in UPK II-Cre;LSL-K-rasG12D lungs.
The laminin and nidogen/entactin networks, usually confined to
Figure 2. Urothelial hyperplasia in the UPK II-Cre;LSL-K-rasG12D mice. A: Urothelial-restricted expression of K-rasG12D. B–E: H&E analysis of
bladders (X200) reveals a hyperplastic urothelium at E17.5 (B,C) and P1 (D,E) (black arrows). F: Differences in urothelial cellularity (cells/0.15 mm2)
between UPK II-Cre;LSL-K-rasG12D mice and controls were significant both at E17.5 (n = 2/group; *, P= 0.05) and P1 (n.6/group; **, P,0.0001); bars,
SEM. G–H: BRDU staining of bladder (X200) showing a higher proliferation in E17.5 UPK II-Cre;LSL-K-rasG12D mice (urothelium limit is marked with a
blue line). The mean number of BrdU positive nuclei/200 mm of urothelium was significantly higher than in controls (n = 10; 662 positive nuclei/
200 mm vs 1.3360.81; P= 0.01).
doi:10.1371/journal.pone.0095888.g002
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epithelial and vascular basement membranes (BM), were altered in
E17.5 lungs, with more of a stromal and diffuse distribution
(Figure 4A–F). Differences in the distribution of collagen IV were
not evident, but a less homogeneous staining was observed in UPK
II-Cre;LSL-K-rasG12D mice (Figure 4E–F).
Due to observed laminin and nidogen (normal constituents of
vascular BM) abnormalities, we next examined the integrity of the
blood vessels. Immunohistochemistry analysis for CD34
(Figure 4G–H) and immunofluorescence analysis for CD31
(Figure 4I–J), revealed abnormalities in the lungs of UPK II-
Cre;LSL-K-rasG12D mice at E17.5. While a normal double capillary
network circling terminal spaces was observed in controls, in the
lungs of the UPK II-Cre;LSL-K-rasG12D mice, capillary network
distribution was diffuse and less organized, with vessels not limited
to just subepithelial areas but frequently present in the stromal
areas (Figure 4G-I). However, a difference in the lung VEGF
Figure 3. Lung phenotype of UPK II-Cre;LSL-K-rasG12D mice. A–B: Representative H&E stained sections showing normality of lung (X200)
morphology in UPK II-Cre;LSL-K-rasG12D when compared with controls at E14.5 (pseudoglandular stage). C–H: Formation of air spaces was impaired in
lungs (X100) of UPK II-Cre;LSL-K-rasG12D mice at E17.5 (C,D) and E19.5 (E,F), reflecting a defective septation process. P1 lung morphology was also
different between controls and transgenic mice, which exhibited an enlargement and simplification of sacculi (G,H). I–J: Morphometric analysis of
lung sections showed a decreased total air space (I) and mean alveolar (saccular) area (J) in UPK II-Cre;LSL-K-rasG12D mice at E17.5 (n = 5); the
impairment of air space development led to an increased total air space area and mean alvelolar area in the early postnatal period (P1; n = 12) in
transgenic mice when compared to controls; bars, SEM. K–L: Masson tri-chrome staining of day P1 UPK II-Cre;LSL-K-rasG12D lungs (X100), showing
absence of fibrosis both in cases and controls. M: The direct expression of K-rasG12D was ruled out with specific PCR showing the absence of
recombination between K-ras and the Lox sequence in lung and placenta.
doi:10.1371/journal.pone.0095888.g003
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expression (Western blot and immunofluorescence) was not
observed between UPK II-Cre;LSL-K-rasG12D and control mice at
day P1 (data not shown).
Absence of kidney, placental or amniotic fluid
abnormalities
Lung morphogenesis can be altered by amniotic fluid (AF)
disorders, especially by oligohydramnios, which can be associated
to kidney agenesis [23,24]. Renal gross appearance, pyelocalicial
distribution and size were normal and no agenesis or other kidney
development defects were observed (Figure 5A–B). AF volume was
not significantly different between UPK II-Cre;LSL-K-rasG12D and
control mice at 17.5 and 14.5 gestation age (Figure S2, A). Since
vessel abnormalities were present in lungs from UPK II-Cre;LSL-K-
rasG12D and protein content of the AF can alter embryo
development, we evaluated VEGF and sFlt1 levels in AF from
gestational day 17.5. This analysis did not reveal any difference in
their levels (Figure S2, C–D). Additionally, since K-ras codon 12
mutations may increase glycolysis [25], we measured (gestation age
17.5) AF lactate concentration. Insignificant differences were
observed between UPK II-Cre;LSL-K-rasG12D (11.163.9 mM) and
controls (10.561.8 mM; P=0.83).
Placental disorders have also been associated with lung dysplasia
[26]. Therefore, we examined placentas at gestational day 19.5.
Placental weight was significantly increased in the UPK II-Cre;LSL-
K-rasG12D mice (123.8618.6 mg vs. 103618.0 mg; P=0.018)
(Figure S2, B). However, placental weight on E14.5 or E17.5
was unchanged with no major defects observed in placenta at the
Figure 4. Disorganization of extracellular matrix and blood vessels in the lungs of UPK II-Cre;LSL-K-rasG12D mice. A-F: Representative
images of immunohistochemistry for pan-laminin (X400) (A,B), and immunofluorescence for entactin (X630) (C,D), showed a different pattern in
E17.5 lung from UPK II-Cre;LSL-K-rasG12D mice, with a less organized network and stronger expression in the stroma. Immunofluorescence for collagen
IV (X630) (E,F) showed a similar, but less prominent, pattern. G-J: CD34 staining (G,H) and CD31 immunofluorescence (I,J) of lung vessels at E17.5
(X400) also exhibited a disorganized distribution in UPK II-Cre;LSL-K-rasG12D mice, with more mesenchymal vessels and a disruption of the normal
subepithelial double capillary network (black arrows in G).
doi:10.1371/journal.pone.0095888.g004
Figure 5. Normal kidney development in UPK II-Cre;LSL-K-rasG12D
mice. A-B: H&E stained kidney sections from day E17.5 showing normal
development both in UPK II-Cre;LSL-K-rasG12D mice and controls (X200).
doi:10.1371/journal.pone.0095888.g005
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macroscopic level or microscopically in the labyrinth and
spongiotrophoblast layers of the placenta (Figure S2, E-J). The
absence of the K-rasG12D-Lox1A sequence in placentas from the
UPK II-Cre;LSL-K-rasG12D mice (E17.5 and 19.5) was also
confirmed (Figure 3M).
Evidence of laminin/E-cadherin fragmentation in the
lungs and altered proteases activity in the amniotic fluid
of UPK II-Cre;LSL-K-rasG12D mice
To determine whether ECM defects in the lung was related to
ECM degradation, we performed WB analysis of the ECM
components in lungs of P1 UPK II-Cre;LSL-K-rasG12D mice and
their littermate controls. When lung laminin b1 chain was
evaluated (full length molecular weight (mw): 205 kDa), we
consistently found an additional band of around 30–35 kDa,
suggestive of fragmentation of laminin b1 in the lungs of UPK II-
Cre;LSL-K-rasG12D mice (Figure 6A). These findings also correlated
with an altered laminin b1 pattern in E17.5 lung basal membranes
(Figure 6B). Immunoblotting for E-cadherin (mw: 135 kDa) clearly
identified a strong 53 kDa and 32 kDa degradation band in lung
samples from the UPK II-Cre;LSL-K-rasG12D mice (Figure 6C). No
depletion of full-length laminin b1 or E-cadherin bands was
observed, probably reflecting their higher levels of expression
observed with immunohistochemistry. Since matrix metallopro-
teases (MMP) expression may be induced by K-ras mutations [27]
and AF in late gestation is predominantly derived from fetal urine
[28], we wondered whether K-ras activation in urothelium resulted
in higher content of proteases in the AF, thus explaining the
degradation of ECM and E-cadherin. The lungs from the UPK II-
Cre;LSL-K-rasG12D mice before gestation age of E15 appeared
normal and correlated with the fact that both maturation of
urothelium and expression of uroplakin II occur after E15 stage of
the embryo (Figure 4A–B).
We tested AF samples for gelatinolytic and caseinolytic activity
(gestational days 17.5 and 19.5). Gelatin zymography of AF
revealed intense MMP-2 and pro-MMP-2 bands both in UPK II-
Cre;LSL-K-rasG12D and control mice. Slight differences in proteo-
lytic activity were observed between UPK II-Cre;LSL-K-rasG12D and
controls: a 20 kDa protein with gelatinolytic activity was present in
the UPK II-Cre;LSL-K-rasG12D AF, which was not observed in
casein zymography (Figure S3, A). In addition, two bands with
caseinolytic activity of approximately 80 kDa and 70 kDa were
present in AF of UPK II-Cre;LSL-K-rasG12D mice (Figure S3, B).
However, Western blot analysis for MMP-1, MMP-2, MMP-3,
and MT1-MMP in AF and lung did not show any differences
between the two groups. Bladder expression of MMPs was also
evaluated by immunofluorescence staining, but again, we did not
observe differences in the expression of MMP-1, MMP-3 or
MMP-13 between UPK II-Cre/K-rasG12D and controls (data not
shown).
Discussion
A number of knockout and gain-of-function mouse models have
provided new knowledge regarding the importance of Ras
function, both during development and carcinogenesis. Here we
demonstrated that specific urothelial expression of KrasG12D
disrupted ECM and cell adhesion molecules in the lung and led
to defective lung septation and impaired vascular patterning.
With regard to K-rasG12D expression in urothelium, the
induction of urothelial proliferation is similar to that observed in
other epithelia [9]. Such changes might constitute pre-neoplastic
alterations, although we could not assess its future relevance due to
100% neonatal lethality of UPK II-Cre;LSL-K-rasG12D individuals.
The consequence of urothelial expression of KrasG12D is the
induction of a lung morphogenesis defect. We observed differences
in lung morphology starting from E17.5. In that phase of lung
morphogenesis (transition from canalicular to saccular stages or
Figure 6. Fragmentation of ECM components in lungs of UPK II-Cre;LSL-K-rasG12D mice. A: Total protein lysates from whole lung were
analyzed by Western blot for for laminin b-1 from P1 UPK II-Cre;LSL-K-rasG12D mice and control (Cre-) mice, showing an additional low molecular
weight (mw) band (35 kDa) which suggest fragmentation. B: Representative images of immunofluorescence for laminin b-1 (X200) showed a
disorganized membrane pattern in E17.5 lung from UPK II-Cre;LSL-K-rasG12D mice. C: WB for lung E-cadherin in P1 lung, with an increase in low mw
bands. (53 and 32 KDa) also in UPK II-Cre;LSL-K-rasG12D mice.
doi:10.1371/journal.pone.0095888.g006
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early saccular phase) [21] distal air spaces are generated not via
branching mechanism but via septation. The finding of decreased
formation of air spaces at E17.5 and E19.5 clearly correlates with a
diminished number and a larger size of terminal air spaces at P1 in
UPK II-Cre;LSL-K-rasG12D mice. This phenotype of normal lung
branching but late impairment in the process of septation is clearly
different from the early branching defects observed in lungs
expressing K-rasG12D [8]. Additionally, we did not detect K-rasG12D-
Lox1A sequence in lungs of UPK II-Cre;LSL-K-rasG12D mice further
confirming that lung morphogenesis impairment observed in this
study is not dependent on KrasG12D expression in lung tissue. The
urothelial specificity of this model is further supported by our
previous studies with UPK II-SV40 mice, which displayed a
constant phenotype [17] when compared to previous models using
the miscloned UPK II promoter [29], suggesting that the
miscloned lesion in UPKII promoter affected activity and
specificity [17,29]. These mice, with exactly the same UPK II
promoter, revealed a significant cancer phenotype in urothelium
with no lung defects [17]. We also excluded other potential causes
of lung developmental defects, such as amniotic fluid disorders,
impaired kidney morphogenesis or urinary tract obstruction.
Previous reports have demonstrated that germline expression of K-
rasG12D mutation induces lethal placental defects [8]. Therefore, in
this study we further confirmed the absence of the K-rasG12D-Lox1A
sequence in placentas from the UPK II-Cre;LSL-K-rasG12D mice. No
differences in placental morphology were observed, excluding
placental diseases as the cause of lung dysplasia [26].
The development of lung is a complex process in which
interactions between extracellular matrix (ECM) and epithelial/
endothelial cells are of crucial importance. Different mouse models
have explored the role of ECM components in the fetal lung
development and function, especially collagen IV, entactin and
laminin [21]. Lungs from UPK II-Cre;LSL-K-rasG12D reveal a
significant alteration in the ECM content, vascular basement
membranes and lung capillary network.
Degradation of ECM is performed by many proteases,
including the matrix metalloproteases (MMP). Oncogenic activa-
tion, and in particular K-ras mutations, induces MMP expression
in several tumors [27] and also increase their functional levels in
physiological fluids, including the urine [30]. The source of AF in
the second half of gestation is predominantly via urine production
by the fetus [28]. Although the fetal flow of lung liquid is
predominantly outward [31], limited contact between amniotic
fluid and lung fluid also exists and fetal breathing movements
might introduce proteases-enriched AF to the lung. The absence
of any lung defects in similar UPK II mouse models when
urothelial proliferation and carcinoma are present (UPK II-SV40
mice) [17], also suggests that mutated K-ras expression, and not
proliferation per se, leads to impaired lung development in this
setting. The appearance of lung changes in UPK II-Cre;LSL-K-
rasG12D mice only after day E17.5, which is temporally coincident
with the urothelium formation and uroplakin II expression, further
supports the contribution of urine-derived AF to the observed lung
morphogenetic defects. A direct degradation of ECM as a
causative mechanism is suggested by the data showing fragmen-
tation of ECM and adhesion molecules, together with the absence
of inflammatory activity or fibrosis in embryo or newborn UPK II-
Cre;LSL-K-rasG12D lungs, although the analysis of proteolytic
activity in AF is not conclusive and further mechanistic
explanations are needed.
Lungs of UPK II-Cre;LSL-K-rasG12D mice show enlargement and
simplification of air spaces and a dysmorphic vascular network.
This morphologic pattern resembles the pathology of early stages
of human bronchopulmonary dysplasia (BPD) [15,16]. BPD is
associated with premature births (under 30 weeks) [32], corre-
sponding to the late canalicular or early saccular stages of lung
development [21], and some experimental models further support
a stage-specific lesion at the saccular stage as the critical antenatal
event for BPD [33]. These stages are associated with apposition of
vessels and air spaces, thereby stressing the importance of the
interplay between lung vascular and airway morphogenesis [34] in
the pathogenesis of BPD [35,36]. Interestingly, this stage in
humans corresponds to a stage between E16.5 and post-natal day
5 in mice. It is at this stage that we observe pulmonary and
vascular changes, further supporting the similarity of UPK II-
Cre;LSL-K-rasG12D mice to human BPD.
Both ECM deposition and MMP activity have been shown to be
critical for septation processes in lung morphogenesis [21,22,37],
and some clinical studies suggest a role for them in BPD
pathogenesis [38]. Additionally, experimental models of lung
ECM disruption have revealed a connection between abnormal
ECM and the defective development of airways [39], and ECM
fragmentation has been shown as a mechanism for air space
enlargement in other contexts such as pulmonary emphysema
[40]. Our findings are also similar to previous reports that have
identified a potential role of MMP-mediated E-cadherin shedding
in lung morphogenesis [41]. Here we suggest the possibility that
ECM disruption in the lungs of the UPK II-Cre;LSL-K-rasG12D mice
could be the mechanism explaining an impaired lung septation.
The vascular changes associated with human BPD are complex
[42], and a role for VEGF has been speculated [32,43]. We did
not find a difference in the VEGF levels within the AF or the lung.
However, vascular defects could be due to disruption of laminin
and other components of vascular BM [44].
In conclusion, our results suggest that in the UPK II-Cre;LSL-K-
rasG12D mice, lethal lung morphogenesis defect may be explained
by altered metabolism of lung extracellular matrix and cell
adhesion molecule, E-cadherin, leading to generalized ECM and
vascular disruption. Our data, taken together with previous reports
on the potential role of urothelium in urinary protein secretion
[45], point to altered proteolytic activity in the AF as one of the
causes of newborn alvealorization defects. The exact relevance of
these mechanisms for human BPD pathogenesis needs more
investigation.
Supporting Information
Figure S1 Human bronchopulmonary dysplasia (BPD).
A: A case of human bronchopulmonary dysplasia (gestational age:
24 weeks) treated with mechanical ventilation, showing enlarge-
ment and simplification of alveoli with moderate interstitial fibrosis
(X100). B: A later stage of human BPD (gestational age: 31 weeks);
only small air spaces are evident, with extensive fibrosis that
impaired air exchange (X100).
(TIF)
Figure S2 Amniotic fluid and placenta in the UPK II-
Cre;LSL-K-rasG12D mice. A: Similar AF volumes of UPK II-
Cre;LSL-K-rasG12D mice and controls on gestational days 14.5
(n = 9) and 17.5 (n = 17). B: Increased placental weight (p = 0.018)
of day 19.5 UPK II-Cre;LSL-K-rasG12D mice (n= 24) and similar
weights on days 14.5 (n = 8) and 17.5 (n = 17). C–D: Similar AF
concentration of VEGF (C; n = 4) and sFlt1 (D; n= 4). E–J: Low
power (X25) H&E stained placenta sections from day 19.5 (E–F)
and higher power (X200) images showing a detail of labyrinth (G–
H) and spongiotrophoblast (I–J) with normal histology in both
groups. Bars, SEM.
(TIF)
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Figure S3 Altered protease activity in amniotic fluid of
UPK II-Cre;LSL-K-rasG12D mice. A–B: Gelatin (A) and casein
(B) zymography of days 17.5 and 19.5 amniotic fluid show
additional bands of gelatinolytic (20 kDa) and caseinolytic (70–
80 kDa) activity in AF of UPK II-Cre;LSL-K-rasG12D mice when
compared with controls.
(TIF)
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